文献速递神经核医学肿瘤 PET/CT

基于免疫PET显像的靶向胶质母细胞瘤干细胞内皮素A受体的抗体及其Fab的临床前原位模型药代动力学特征

ImmunoPET imaging-based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2023-06-07

本研究在患者来源Gli7胶质母细胞瘤干细胞原位异种移植小鼠模型中,将靶向内皮素A受体的嵌合抗体xiRA63及其Fab(ThioFab-xiRA63)与89Zr结合,经静脉注射后用µPET-CT显像并分析组织生物分布与药代动力学。结果显示[89Zr]Zr-xiRA63能穿过脑肿瘤屏障,肿瘤摄取优于[89Zr]Zr-ThioFab-xiRA63,展示出特异性靶向内皮素A受体阳性肿瘤的高潜力。

要点

  • 在Gli7胶质母细胞瘤干细胞原位模型中,[89Zr]Zr-xiRA63可穿过脑肿瘤屏障。
  • [89Zr]Zr-xiRA63的肿瘤摄取优于[89Zr]Zr-ThioFab-xiRA63。
  • 该研究提示[89Zr]Zr-xiRA63有靶向内皮素A受体阳性肿瘤的潜力。

核心结论

  • 本研究显示[89Zr]Zr-xiRA63在特异性靶向内皮素A受体阳性肿瘤方面具有高潜力,从而提出了检测和治疗内皮素A受体阳性胶质母细胞瘤干细胞的可能性,或可改善胶质母细胞瘤患者的管理。

研究设计与样本

  • 临床前研究,在患者来源Gli7胶质母细胞瘤干细胞原位异种移植小鼠模型中,将靶向内皮素A受体的嵌合抗体xiRA63及其Fab(ThioFab-xiRA63)与89Zr结合,经静脉注射后进行µPET-CT显像并分析组织生物分布与药代动力学参数。

主要发现

  • 放射性配体经静脉注射后随时间进行µPET-CT显像,组织生物分布与药代动力学分析显示[89Zr]Zr-xiRA63能够穿过脑肿瘤屏障。
  • [89Zr]Zr-xiRA63的肿瘤摄取优于[89Zr]Zr-ThioFab-xiRA63。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The resistance of glioblastoma stem cells (GSCs) to treatment is one of the causes of glioblastoma (GBM) recurrence. Endothelin A receptor (ETA) overexpression in GSCs constitutes an attractive biomarker for targeting this cell subpopulation, as illustrated by several clinical trials evaluating the therapeutic efficacy of endothelin receptor antagonists against GBM. In this context, we have designed an immunoPET radioligand combining the chimeric antibody targeting ETA, chimeric-Rendomab A63 (xiRA63), with 89Zr isotope and evaluated the abilities of xiRA63 and its Fab (ThioFab-xiRA63) to detect ETA+ tumors in a mouse model xenografted orthotopically with patient-derived Gli7 GSCs. RESULTS: Radioligands were intravenously injected and imaged over time by µPET-CT imaging. Tissue biodistribution and pharmacokinetic parameters were analyzed, highlighting the ability of [89Zr]Zr-xiRA63 to pass across the brain tumor barrier and achieve better tumor uptake than [89Zr]Zr-ThioFab-xiRA63. CONCLUSIONS: This study shows the high potential of [89Zr]Zr-xiRA63 in specifically targeting ETA+ tumors, thus raising the possibility of detecting and treating ETA+ GSCs, which could improve the management of GBM patients.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Hautiere M, Vivier D, Pineau D, et al. ImmunoPET imaging-based pharmacokinetic profiles of an antibody and its Fab targeting endothelin A receptors on glioblastoma stem cells in a preclinical orthotopic model. Eur J Nucl Med Mol Imaging. 2023. PMID: 37280303. doi:10.1007/s00259-023-06268-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。